SHANGHAI, June 3, 2021 /PRNewswire/ -- Zhongchao Inc.
(NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare
services company offering online healthcare information,
professional training and educational services, announced the
on-going one-year joint project of leukemia diagnosis and
treatment courses (the "Project") that the Company has been hosting
with Beijing Bethune Charitable Foundation ("Bethune Foundation")
and BeiGene Pharmaceutical (Shanghai) Co., Ltd. ("BeiGene Shanghai"), a
subsidiary of BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160)
("BeiGene").
The Project started in December
2020 and will end in December
2021. It provides leukemia practitioners and research groups
with advanced practice improvement courses, standardized diagnosis
and treatment lectures, interactive webcast discussions, and other
academic exchange activities. Zhongchao plans to provide 100
academic exchange sessions. In each session, Zhongchao invites one
expert as a moderator to elaborate on leukemia diagnosis and
treatment guidelines, and three speakers to share specific leukemia
treatment case studies. Zhongchao expects to have more than 400
experts and speakers participating in the Project and presenting
about 255 case studies by the end of the Project. The Project is
available for more than 10,000 clinicians through live broadcast.
The Project combines detailed interpretation of leukemia diagnosis
and treatment guidelines with case studies and provides a platform
to share latest cutting-edge solutions to leukemia targeted
immunotherapy and to engage participants in in-depth discussions
through clinical practice courses.
Weiguang Yang, Chairman and Chief
Executive Officer of Zhongchao, commented, "We are honored to work
with Bethune Foundation and BeiGene Shanghai to host this Project
to share the useful information among medical professionals in
order to improve clinicians' practice in leukemia diagnosis and
treatment and narrow the gap between hospitals in the third- and
fourth-tier cities and the first- and second-tier cities in
China."
About BeiGene
BeiGene is a global, science-driven biotechnology company
focused on developing innovative and affordable medicines to
improve treatment outcomes and access for patients worldwide. With
a broad portfolio of more than 40 clinical candidates, they are
committed to expediting the development of their diverse pipeline
of novel therapeutics through collaborations or their own internal
capabilities, with the aspirational goal of radically improving
access to medicines for two billion more people by 2030. BeiGene is
a headquarter-less company by design, with a growing global team of
approximately 6,000 colleagues across five continents. To learn
more about BeiGene, please visit www.beigene.com.
About Zhongchao Inc.
Incorporated in 2012 with headquarter offices
in Shanghai and Beijing, China, Zhongchao
Inc. is an online provider of healthcare information,
professional training and educational services to healthcare
professionals under its "MDMOOC" platform (www.mdmooc.org) and to
the public under its "Sunshine Health Forums" platform
(www.ygjkclass.com) in China. More information about the
Company can be found at its investor relations website
at http://izcmd.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may," "will," "intend," "should," "believe," "expect,"
"anticipate," "project," "estimate" or similar expressions that do
not relate solely to historical matters, it is making
forward-looking statements. Forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties that may cause the actual results to differ
materially from the Company's expectations discussed in the
forward-looking statements. These statements are subject to
uncertainties and risks including, but not limited to, the
following: the Company's goals and strategies; the Company's
future business development; product and service demand and
acceptance; changes in technology; economic conditions; the growth
of the professional training and educational services market
in China and the other international markets the Company
plans to serve; reputation and brand; the impact of competition and
pricing; government regulations; fluctuations in general economic
and business conditions in China and the international
markets the Company plans to serve and assumptions underlying or
related to any of the foregoing and other risks contained in
reports filed by the Company with the SEC, the length and
severity of the recent coronavirus outbreak, including its impacts
across our business and operations. For these reasons, among
others, investors are cautioned not to place undue reliance upon
any forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the SEC,
which are available for review at www.sec.gov. The Company
undertakes no obligation to publicly revise these forward–looking
statements to reflect events or circumstances that arise after the
date hereof.
For more information, please contact:
At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987
Investor Relations: Sherry Zheng
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386
View original
content:http://www.prnewswire.com/news-releases/zhongchao-inc-announces-the-on-going-one-year-leukemia-education-project-with-bethune-foundation-and-beigene-shanghai-301304691.html
SOURCE Zhongchao Inc.
